Arvinas (ARVN) Insider Linda Bain Buys 22,714 Shares

Arvinas, Inc. (ARVN) insider Linda Bain recently expanded her position in the biotechnology firm. According to a recent filing, Bain acquired 22,714 shares of the company on June 24, 2026. This transaction was part of a coordinated day of buying by several members of the Arvinas team.

Broad Insider Buying Activity at Arvinas

Linda Bain's acquisition was not an isolated event. On June 24, 2026, several other insiders reported increasing their stakes in the company. Everett Cunningham and Kennedy Edward Moore JR. each added 15,527 shares to their holdings. Meanwhile, Leslie Norwalk and Laurie Smaldone Alsup also purchased 15,527 shares each on the same date. Briggs Morrison joined the group by acquiring 22,714 shares. None of these transactions were conducted under a Rule 10b5-1 trading plan, which is a pre-set schedule insiders sometimes use to time their trades.

Arvinas Stock Performance and Valuation

On Saturday, shares of Arvinas were priced at $8.00. The stock has experienced some volatility over the past year, trading between a low of $6.97 and a high of $14.51. At its current price level, the company has a price-to-earnings (P/E) ratio of 31.9, which measures its share price against its earnings per share of $0.26. The stock is currently sitting below its 50-day moving average of $8.70 and its 200-day moving average of $10.37, two metrics that traders watch to gauge price trends.

Recent Earnings and Financial Health

In its most recent financial reports, Arvinas reported revenue of $316.7 million, representing a growth of 10.1% compared to the previous period. The company maintains a net margin of 2.9% and a return on equity of 1.6%. Arvinas also shows a high level of liquidity with a quick ratio of 7.54, which helps the firm manage its short-term debt obligations. Investors are looking ahead to November 4, 2026, when the company is expected to release its next set of quarterly earnings results.

Analysts Set New Price Targets

Several investment firms have recently updated their views on Arvinas. On August 10, 2026, Citigroup kept its Buy rating but adjusted its price target to $21.00. That same day, Evercore ISI Group maintained an Outperform rating with a $14.00 target. Earlier in August, Wedbush reiterated a Neutral stance with a $12.00 target, while BTIG stuck with a Buy rating and an $18.00 target. Wells Fargo moved the stock to an Equal-Weight rating on August 5, setting an $11.00 target. Across 14 analysts, the general consensus remains a buy.

About Arvinas, Inc.

Arvinas is a New Haven-based biotech company focused on protein degradation. Instead of just blocking harmful proteins that cause diseases like cancer or Parkinson's, the company develops therapies designed to trigger the body's own natural disposal system to remove them entirely. They currently have several clinical programs in development, including partnerships with major drugmakers like Pfizer and Bayer.

What to Watch at Arvinas, Inc.

The cluster of insider buying in June shows a collective increase in ownership by the leadership team at a time when the stock is trading toward the bottom of its yearly range. While these filings show past actions, the upcoming earnings report in November will provide the next major look at the company's financial progress and the status of its clinical drug pipeline.